Abeona Therapeutics (ABEO) - רווח נקי למניה (EPS TTM)

Abeona Therapeutics (ABEO) controls the niche of cell therapy for skin pathologies by integrating the EB-101 drug into surgery. Net income per share over the last 12 months on this chart on GURU.Markets reflects a trend where -1.10 becomes the new value of the indicator. This is driven by the expansion of Pz-cel in the orphan market and the absence of geopolitical risks due to the localization of production in the US.
פילוחי מדדים מקיפים ואנליטיקה עבור Abeona (ABEO)

Abeona Therapeutics (ABEO) ensures the stable production of orphan drugs through its own high-tech facility in Ohio featuring autonomous cleanrooms. The business's annual equity income, reflected via the rolling 12-month net income per share, allows for a real-time assessment of this infrastructure's efficiency, where an upward trend confirms asset capitalization, while a downward reversal signals risks of company overvaluation.